ES2131468B1 - USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES. - Google Patents

USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Info

Publication number
ES2131468B1
ES2131468B1 ES9701212A ES9701212A ES2131468B1 ES 2131468 B1 ES2131468 B1 ES 2131468B1 ES 9701212 A ES9701212 A ES 9701212A ES 9701212 A ES9701212 A ES 9701212A ES 2131468 B1 ES2131468 B1 ES 2131468B1
Authority
ES
Spain
Prior art keywords
melatonin
treatment
neurodegenerative diseases
hormone
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9701212A
Other languages
Spanish (es)
Other versions
ES2131468A1 (en
Inventor
Sanchez Carmen Rodriguez
Barrallo Juan Carlos Mayo
Menendez Rosa Maria Sainz
Gonzalez Isaac Antolin
Marban Higinio Uria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Oviedo
Original Assignee
Universidad de Oviedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Oviedo filed Critical Universidad de Oviedo
Priority to ES9701212A priority Critical patent/ES2131468B1/en
Publication of ES2131468A1 publication Critical patent/ES2131468A1/en
Application granted granted Critical
Publication of ES2131468B1 publication Critical patent/ES2131468B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Uso de la melatonina en el tratamiento de las enfermedades neurodegenerativas. La invención se refiere al uso de la melatonina en la preparación de composiciones útiles para prevenir y para evitar el progreso de los síntomas en las enfermedades neurodegenerativas. También se refiere al uso de esta hormona en combinación con otros antioxidantes o con otros inhibidores de la proliferación celular para el tratamiento y prevención de dichas alteraciones. El uso de esta hormona tiene las ventajas sobre otros medicamentos utilizados en dichos tratamientos de que es un agente antioxidante e inhibidor de la proliferación celular endógeno que no posee efectos secundarios, atraviesa fácilmente la barrera hematoencefálica, y ejerce sus efectos en todos los compartimentos celulares.Use of melatonin in the treatment of neurodegenerative diseases. The invention relates to the use of melatonin in the preparation of compositions useful for preventing and preventing the progression of symptoms in neurodegenerative diseases. It also refers to the use of this hormone in combination with other antioxidants or with other inhibitors of cell proliferation for the treatment and prevention of said alterations. The use of this hormone has the advantages over other drugs used in such treatments in that it is an antioxidant agent and inhibitor of endogenous cell proliferation that has no side effects, easily crosses the blood-brain barrier, and exerts its effects on all cell compartments.

ES9701212A 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES. Expired - Fee Related ES2131468B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9701212A ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9701212A ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Publications (2)

Publication Number Publication Date
ES2131468A1 ES2131468A1 (en) 1999-07-16
ES2131468B1 true ES2131468B1 (en) 2000-04-01

Family

ID=8299558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9701212A Expired - Fee Related ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Country Status (1)

Country Link
ES (1) ES2131468B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209649B1 (en) * 2002-12-09 2005-03-16 Carlos Arana Molina (Titular Al 25%) USE OF MELATONINE FOR BUCODENTAL HYGIENE FOR HUMAN AND VETERINARY USE AS AN ACTIVE PRODUCT.
ES2213473B1 (en) * 2002-12-31 2005-10-01 Carlos Arana Molina (Titular Al 25%) USE OF MELATONIN FOR THE OSEA REGENERATION OF HUMAN AND VETERINARY USE AS AN ACTIVE PRODUCT.

Also Published As

Publication number Publication date
ES2131468A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
UY26092A1 (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES
ES2191152T3 (en) COMBINED THERAPY FOR THE TREATMENT OF PSYCHOSIS.
ES2377720T3 (en) AGON�? STICOS ANTIBODIES EPHA2 AND METHODS OF USE OF THE SAME.
ES2157601T3 (en) USE OF ANTI-MICROTUBLE AGENTS TO TREAT OR PREVENT MULTIPLE SCLEROSIS.
AR002007A1 (en) A THERAPEUTIC COMPOSITION OF TOPICAL APPLICATION CONTAINING AN ANTAGONIST OF SUBSTANCE P AND USE OF SUCH ANTAGONIST FOR THE PREPARATION OF SUCH COMPOSITION TO DECREASE AND / OR ELIMINATE AN IRRITATING SIDE EFFECT OF A PRODUCT CONTAINED IN IT.
ES2157027T3 (en) OXAZOLIDINONES REPLACED AND ITS USE AS ANTIBACTERIAL PHARMACOS.
PA8443001A1 (en) PREVENTION OF LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
GT199900147A (en) 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
ES2161085T3 (en) FORMULATIONS CONTAINING OXALIPLATIN.
CO5160262A1 (en) PHARMACEUTICAL FORMULATIONS OF CONTROLLED LIBERATION
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
AR021370A1 (en) STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS CONTAINING TAXOID ANTI-NEOPLASIC AGENTS
AR003119A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING VIROSIC INFECTIONS OR INHIBITING THE GROWTH OF TUMORS OR CANCERES WHICH INCLUDE A MIXTURE OF A N-CHLOROPHENYL CARBAMATE OR A N-CHLOROPHENITIC CARBAMATE AND A N- PHOSPHONOGLYCAN FOR DICHAUTIC DURATION INHIBIT THE GROWTH OF TUMORS OR CANCERS
AR002987A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OCCURRING VIRAL INFECTIONS OR TUMORS, COMPOSITION OF UNITARY DOSE THAT INCLUDES IT AND USE FOR SUCH TREATMENT
BR0213181A (en) Cox-2 inhibitor combinations
ES2163795T3 (en) PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND INFECTIONS BY PAPILOMAVIRUS.
BR0307017A (en) fast acting sedative hypnotic agents for anesthesia and sedation
PT1032414E (en) COMBINATION OF AN INHIBITOR OF THE ANGIOTENSIN CONVERSATION ENZYME AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISTURBACTIONS
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
ES2188995T3 (en) USE OF AN INHIBITOR OF THE H +, K + -ATPASA IN THE TREATMENT OF NASAL POLYPS.
AR015945A1 (en) AUTOFOBIC HAIR SPRAY COMPOSITIONS
ES2164447T3 (en) BONE RESORTION INHIBITION PROCEDURE.
AR043660A1 (en) THE TREATMENT OF ALZHEIMER'S DISEASE

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990716

Kind code of ref document: A1

Effective date: 19990716

FD2A Announcement of lapse in spain

Effective date: 20170905